Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains ...

Illumina said adding SomaLogic would support the company’s multiomics strategy and strengthen the value of its NovaSeq X ...

Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein ...

Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation. SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- ...

Recent collaborations highlight a growing interest in building a multiomics-based understanding of health and disease.

Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE ...

The amplicon nanoballs are extracted and sequenced on a conventional Illumina platform. In Phase 3, multimodal data were integrated through a computational pipeline to capture what DNA was found ...

Grail is preparing to file for FDA approval of its Galleri test for detecting multiple cancers from a single blood test after ...

INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.